Anavex Life Sciences Corp (AVXL)

[falconer66a]

If Fragile X, Then Autism?

In this paper (co-authored by Dr. Randi J. Hagerman), Autism Symptoms in Fragile X Syndrome (https://pubmed.ncbi.nlm.nih.gov/28617074/), the first sentence of the abstract states, “Fragile X syndrome (FXS) is recognized as the most common genetic cause of intellectual disability and autism spectrum disorder (ASD).”

As the paper will describe, fragile X syndrome, in many cases, is connected to, or is a comorbidity of autism spectrum disorder.

Because the two disorders are closely related, might it turn out that individuals with other forms of autism will be helped with blarcamesine therapy? Dr. Hagerman has already spoken of her support of blarcamesine for fragile X (in the human clinical trials she is conducting).

If blarcamesine proves to be a useful, safe, efficacious therapy for most or all forms of autism, what might be the size of that market? What would be the social and economic implications for markedly reducing the numbers and severities of individuals suffering from autism?

Look it up. In a web search engine, query with this question: “Number of Autism Cases in the US.” Or, “Economic Impact of Autism.”

The results of the Anavex fragile X syndrome clinical trial should be illuminating; certainly for fragile X, but perhaps also for other autism forms.